I am guessing mid .007 -.008. We are now in 4Q, with the possiblity of FDA approval and hopefully better international sales, I expect to see some massive buying at these levels.
I think this is a snap reaction to people merely looking at the sales figure and fearing the worst. The report wasn't as bad as the pps is showing. Yes sales numbers dropped but they are still trending above 09 numbers. As indicated in the report they have made a significant change in how they are marketing this product and that has resulted in a temporary lull in sales for the quarter. Only time will tell but I would expect many of the new markets to pick up steam in the next couple quarters. One positive note is that contrary to much of the fear talk there has been no dilution. O/S is still shy of the 1.5 Bil mark. This is still classified as a start up company and although they are now into the sales phase they have had to invest a significant amount into marketing and brand recognition. As the saying goes "you have to spend money to make money". Unfortunately there isn't much pending in the next quarter except FDA clearance which will shoot the pps up until year end report so it still may be a bleak Christmas for us longs but I am buying as much as I can at these prices because things will turn around eventually. IMHO GLTA
News 
Market Data 
Discover 
AI
